Cisplatin + pemetrexed as first-line therapy for advanced NSCLC

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.593, 2009-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pemetrexed + cisplatin: first-line for malignant pleural mesothelioma

By  

Inpharma, Vol. 1, Iss. 1404, 2003-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Cetuximab FLEXes muscle in first-line advanced NSCLC

By  

Inpharma, Vol. 1, Iss. 1641, 2008-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

FOLFOX4 feasible first-line therapy for advanced gastric cancer

By  

Inpharma, Vol. 1, Iss. 1498, 2005-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Anastrozole: first-line therapy for advanced breast cancer?

By  

Inpharma, Vol. 1, Iss. 1270, 2001-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Pemetrexed plus either cisplatin or carboplatin are active and well tolerated first-line treatments of extensive-stage small-cell lung cancer

By  

Inpharma, Vol. 1, Iss. 1563, 2006-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite